Introduction
According to the 2012 EU Ageing Report [1] , the age structure of the European population is projected to change dramatically in the coming decades, with older people accounting for an increasing share of the population. The percentage of citizens aged over 65 years is predicted to rise from 18% of the current population to 30% in 2060, whereas the percentage of over-80s will increase from 5 to 12% during the same time period ( fig. 1 ) [1] . The population pyramids in figure 2 represent the current and predicted age structure in the EU by 2060. These demographic trends suggest an impending scenario characterised by an increase in age-related disability and dependence, which will ultimately impact not only on the wellbeing of the individuals affected, as disability is a major factor determining a low quality of life, but also on healthcare systems, putting at risk their sustainability [2] . Nevertheless, recent data suggest that this tendency can change, providing the opportunity of living long lives in healthy, functional conditions [3] . Hence, the above demographic scenario entails significant individual and societal challenges and calls for prompt preventive actions.
Once established, disability is hard to reverse. This is one of the main reasons that make prevention the core factor in the fight against disability in older adults, with the identification of conditions preceding the development of disability being an essential requisite to achieve this goal in an effective manner. Frailty is the most important risk factor for the development of non-catastrophic disability [4] . Thus, the identification of risk factors for frailty, the improvement in the accuracy of the diagnosis of frailty and the best knowledge of factors predicting the evolution from frailty to disability are necessary steps to be covered. Currently, assessment of frailty relies primarily on measuring functional parameters such as weight loss, gait speed and grip strength. However, it is now becoming increasingly recognised that the clinical utility of such parameters in terms of risk prediction, diagnosis and prognosis of frailty is limited. To improve this situation, we have set up the FRAILOMIC Initiative. This is an international, large-scale, multi-endpoint, communityand clinic-based research study funded by the European Commission, whose aim is to develop validated measures of both classic and 'omics'-based laboratory biomarkers, which may be able to predict the risk of frailty, improve the accuracy of its diagnosis in clinical practice and provide a prognostic forecast on the onset of disability. In this viewpoint article, we describe the rationale, objectives and principal biomarkers that will be measured by the study.
The FRAILOMIC Initiative adheres to the following basic definition of frailty: 'an age-associated syndrome characterised by a decrease of biological reserve and resistance to stressors due to functional decline of several physiological systems and placing the individual at enhanced risk of disability, hospitalisation and death' [5] . Additionally, in keeping with the definitions released by the International Classification of Impairments, Disabilities and Handicaps [6] , FRAILOMIC defines disability as 'any restriction or lack (resulting from an impairment) of ability to perform an activity in the manner or within the range considered normal for a human being'. However, because the participating cohorts have originally operationalised this definition in different ways, for the purposes of this study, incident disability has been defined as the appearance of a new dependency for basic activities of daily living.
Frailty as a Precursor of Disability: A Rationale for the FRAILOMIC Initiative
One of the main features that characterises the health status of the elderly is its large heterogeneity in terms of the effects that ageing has on the individuals' quality of life, functional limitation and the type of diseases and conditions by which they are affected. Although health status is one of the major determinants of disability, the relation is non-linear, and the onset and presentation of disability cannot be reliably predicted from clinical diagnosis alone [7] . Moreover, the capacity of health status determination and chronic disease to predict disability diminishes as the age of the population increases. It also appears that physical and cognitive factors contributing to functional decline and disability interact, thus suggest-ing that preventive care and rehabilitation of older people should take into account these cofactors for increased dependence. This would imply the need for a personalised medicine approach, taking into account patient stratification and a deeper understanding of which functional biomarkers may be prognostic of disability in older individuals, and hence offer an opportunity for its prevention. In this scenario, frailty has emerged as a relevant concept, as it predicts the risk for adverse clinical outcomes like death, disability, falls and hospitalisation [8] and provides opportunities for intervention [9] . It is becoming increasingly clear that there is a need to expand the concept of frailty from epidemiology to clinical practice [10] . In this regard, several studies have demonstrated some prognostic usefulness of conceptualising frailty in the context of predicting risk in patients undergoing surgical procedures [11] , those receiving treatment for cardiovascular disease [12] and frail older cancer patients likely to develop severe toxicity and side effects in response to aggressive treatment [13] .
The above considerations have led to the concept of defining frailty as a precursor to overt disability. According to its definition, frailty is envisaged as a recognisable phenotypic presentation encompassing physiological and psychological changes consequent upon ageing, lifestyle factors, clinical conditions and interactions among them [7, 14] . In contrast with chronic disease, the predictive capacity of frailty for adverse outcomes like death or disability is known to increase as the age of the population is higher [15] . The prevalence of frailty in people aged >65 years is reportedly high and increases with ageing [8, 16] . Irrespective of the conceptual framework, when an individual passes the threshold for frailty and disability emerges, recovery is unlikely -especially as the age of the patient, the degree of disability and its duration increase further [17] . It is also known that frailty is a major predictor of institutionalisation [odds ratio (OR) vs. robust individuals, 8.6; 95% confidence interval (95% CI), 4.9-15.2] and death (OR, 7.3; 95% CI, 4.7-11.4) and that the relative risks persist after adjustment for sex, age, comorbid conditions and poor self-rated health [18] . Furthermore, in a study that investigated the patterns of functional decline in elderly persons during their final year of life, frailty as an illness trajectory was approximately 8 times more likely than other trajectories like cancer or organ failure to predict dependency in activities of daily living (OR, 8.3; 95% CI, 6.5-10.7). At the time of death, frail individuals were also relatively more disabled than those who died of cancer and/or organ failure [19] . Frailty may precede disability and other clinical outcomes by many years [8] , and its early detection is clearly of importance to prevent disability [9] . Although it is widely recognised that progression from frailty to disability is influenced by multiple determining factors including those of genetic, biological and environmental origin, current research on biomarkers that can predict the development of frailty and its response to treatment is largely inconclusive. Moreover, although there is a considerable agreement about the conceptual definition of frailty [14] , when its operational definition is contemplated, some differences emerge [20] . This has led to varying reports of its prevalence in community-dwelling older people, ranging from as low as 2.5% to as high as 25% [16] . Therefore, in order to address these discrepancies, the FRAILOMIC Initiative aims to provide a clinically acceptable nomenclature for frailty, to identify its most prevalent risk factors in an unbiased approach and to explore and define its consequences in measurable, accurate and reproducible terms, adding to the current criteria new 'omicsbased' items.
To address these aims, the FRAILOMIC Initiative has designed four partially overlapping study phases. Phase I is being conducted in currently running prospective cohorts where, as well as conventional biomarkers of frailty, potential 'omics'-derived or hypothesis-driven laboratory biomarkers for this condition are being explored. In phase II, data emerging from phase I will be validated in validation cohorts, and in phase III, best-fit models for tool kits will be devised. It is expected that the study findings will be disseminated at interim intervals throughout the study period and thereafter (phase IV), and that these will provide healthcare policymakers with the tools to target resources and programmes toward elderly individuals who are at obvious risk of developing frailty, in order to reduce the incidence of new-onset dependence.
Defining Frailty: From Clinical to Laboratory Biomarkers
A number of investigations have proposed several readily assessable surrogate markers of frailty including grip strength [21] , gait speed [12] , poor nutritional intake and micronutrient deficiencies [22, 23] . However, there remains neither a consensus definition of frailty nor consensual clinical assessment tools [14] . Moreover, although there is a range of frailty indices that may be useful to predict adverse outcomes, these involve collecting data on a large number of clinical variables and hence may be cumbersome and impracticable for everyday application [24] .
The most accepted physiological framework to explain frailty and its consequences has been proposed by Fried and Walston [25] . According to their description, frailty results from sarcopenia, energetic imbalance and feedback between these factors, the so-called frailty cycle. This state is thought to involve multiple pathways and systems, especially those related to metabolic and nutritional deficiencies, age-associated hormonal derangements and the development of a pro-inflammatory milieu [26] . Examples of these include decline of mitochondrial function [27] , a decrease in circulating levels of testosterone [28] , increased hydrocortisone (cortisol)-dehydroepiandrosterone ratio [5] , increase in circulating levels of estradiol in women [29] , declining serum levels of growth hormone and insulin-like growth factor-1 [30] , elevated interleukin-6 and soluble receptors of tumour necrosis factor-α [31] , vitamin deficiency [23] and increased values of both C-reactive protein and D-dimers [32] .
Derangement of the oxidant/antioxidant balance leading to oxidative stress is also considered an important determinant of frailty. This notion has been strengthened by recent work using patients from the Toledo Study of Healthy Ageing (TSHA), a constituent cohort of the FRAILOMIC Initiative. The TSHA has shown that in geriatric populations oxidative stress is associated with frailty and not with longevity, thus highlighting the possibility that a set of biomarkers might exist which differentiates ageing from frailty at the molecular level [33] .
Alzheimer's disease and cognitive decline [34] as well as cardiovascular diseases [35] and their risk factors, including diabetes mellitus [36] , have been associated with frailty. In turn, frailty has been shown to influence the prognosis of acute cardiovascular events [37] . Furthermore, within the context of frailty, studies have emphasised the contributory role of atherosclerosis [35] and endothelial dysfunction [38] . Therefore, the possibility of detecting biomarkers related to vascular endothelial dysfunction and of atherosclerotic plaque growth or instability could provide clues to identifying individuals at risk of becoming frail and thereby improve their prognosis.
Another important pillar of the FRAILOMIC Initiative is based on the increasing awareness that cellular senescence, a biological process underlying ageing at the cellular level is occurring in almost all organisms including mammals. There is circumstantial evidence that cellular senescence drives organismic ageing and thereby provides the basis for the onset of age-associated pathology and disease. This concept is best illustrated by the demonstration that genetic elimination of senescent cells reduces age-associated pathology in a mouse model of premature ageing [39] . Of particular importance for the FRAILOMIC Initiative concept is the process of endothelial and vascular smooth muscle cell senescence that occurs in the vascular wall. This phenomenon has been extensively described in vivo and has been associated with vascular disease [40] . Cellular senescence can be observed with increasing age in a variety of other tissues. The occurrence of senescent cells correlates well with age-associated diseases and conditions, such as chronic obstructive pulmonary disease, the metabolic syndrome, kidney diseases, Alzheimer's disease and skin ageing. Senescent cells are known to secrete a large panel of bioactive proteins, including proinflammatory cytokines and metalloproteases, referred to as the 'senescence-associated secretory phenotype' (SASP) [41] . It is conceivable that components of the SASP contribute to tissue damage, considered as a driving force for age-associated functional decline.
Aims of the FRAILOMIC Initiative
The principal aim of the FRAILOMIC Initiative is to develop validated measures comprising both classic and 'omics'-based laboratory biomarkers to predict the risk of frailty, improve the diagnostic accuracy of frailty in dayto-day clinical practice and assess the positive effect of a prognostic forecast of frailty on the onset of disability and other adverse outcomes. In order to identify predictive biomarkers, the EU-funded FRAILOMIC Initiative follows an 'omics' approach (genomics, transcriptomics, proteomics and metabolomics, for example), using existing large datasets from previous 'omics' initiatives [42] . These studies have created a wealth of data that, so far, have not been used in the field of frailty research.
The approach taken by the FRAILOMIC Initiative is to predict the risk of frailty, to improve the diagnostic accuracy of frailty in terms of day-to-day clinical practice and to assess the prognosis of frailty in terms of disability and other adverse outcomes. This will allow clinicians to go beyond the traditional disease-based approach to healthcare strategy and toward a strategy based on comprehensive quality of life, since the impact will be on reducing disability. Secondary objectives of the FRAILO-MIC Initiative include assessing interactions among putative biomarkers, nutrition, exercise and their effects on the natural history of frailty. In addition, the potential therapeutic usefulness of identifying frailty status in special older populations such as those with metabolic syndrome, diabetes and cardiovascular disease will be examined. The FRAILOMIC Initiative aims to provide useful tool kits for care providers that will allow them to assess the risk of an older individual developing frailty (i.e. 'risk biomarkers') as well its identification (i.e. 'diagnostic biomarkers'), clinical course (i.e. 'prognostic biomarkers') and likely response to treatment (i.e. 'predictive biomarkers'), thus bridging the gaps between epidemiology and clinical practice.
Participating older adults in the FRAILOMIC Initiative will be recruited from eight established communitybased cohorts, seven of which are European [InChianti, TSHA, ENRICA Study, SardiNIA Study, Three-Cities (3-C), AMI Cohort and the Collaboration on Ageing in Europe (COURAGE)] and one, the Study of Global Ageing and Adult Health (SAGE), represents people from across the globe. These cohorts comprise a total of >75,000 subjects, most of whom (n = 51,860) are aged >65 years. Baseline data (e.g. functional and nutritional status, exercise habits and cardiovascular health) for each of the FRAIL-OMIC participants will be obtained from the original cohort surveys. The main descriptors of the cohorts are summarised in table 1 . In addition, during the study, all adverse outcomes (disability, hospitalisation and death) will be systematically recorded. In phase I of the FRAILO-MIC Initiative, exploratory study subjects will first be stratified as 'non-frail' or 'frail' using Fried's definition such as the presence of at least three criteria presented in table 2 . In non-frail subjects, one of the aims of the study will be to identify biomarkers that are associated with the risk of developing frailty; that is, the expression of these biomarkers will be differentiated between subjects who do and those who do not develop frailty during a 3-year follow-up period. Another study aim in frail and non-frail subjects (matched by sex, age and time of follow-up) is to improve the diagnosis of frailty by identifying biomarkers that are differentially expressed between these two groups, using conditional logistic regression analysis. Lastly, another study aim will be to characterise, using Cox regression analysis, the prognosis of subjects with frailty at baseline by documenting their incidence rates of disability, hospitalisation and death thereafter. Statistical analysis of the data will aim to identify significant relations between target biomarkers and study endpoints, taking into account their diagnostic accuracy (by using receiver operating characteristic curves), diagnostic OR, positive and negative likelihood ratios, positive and negative predictive power as well as sensitivity and specificity. A statistical method devised in-house by the FRAILOMIC Initiative researchers [43] will be adapted to the FRAILO-MIC Initiative in order to minimise false-positive associations and multiple testing challenges occurring when analysing several datasets.
Biomarkers to be initially examined in the FRAILO-MIC Initiative are listed according to their biological functions in table 3 . Although most of these molecules have not been previously studied within the context of frailty, each of them was included after a careful review of the literature having shown a suggested relationship with this condition, its domains or its potential pathophysiological routes. Genomic and transcriptomic investigations of proposed candidate genes will consist of genotyping single nucleotide polymorphisms (SNPs) and assessing gene expression levels. More candidate genes will be investigated as they come to light in the future. SNPs will be analysed using the Veracode platform, which allows the analysis of 48, 96, 144, 192 or 384 SNPs by an allelic discrimination reaction, extension reaction and multiplex PCR with universal primers, while gene expression will be analysed using the OpenArray platform, an arraybased system that applies the real-time polymerase chain reaction technique, and then subjected to bioinformatics analysis. Labelling of telomeres in interphase nuclei will be performed using high-throughput quantitative fluorescence in situ hybridisation so as to determine the percentage of cells with critically short telomeres [44] . Frequency of critically short telomere length has been dem- 189 onstrated to be a more useful determinant of telomere dysfunction than the average telomere length [44] . Since circulating microRNAs in serum or plasma have been identified in the context of senescence, ageing and ageassociated diseases [45] , a miRNome-wide analysis of circulating miRNAs will be investigated in order to identify a miRNA-based signature of frailty. Along the same lines, proteins known to be secreted by senescent endothelial cells will be investigated. In addition, serum levels of HIF-α will be determined and compared with the expression of a panel of target genes. Finally, conventional and innovative laboratory biomarkers will be assessed with standardised and reference techniques, according to the best laboratory practice.
The FRAILOMIC Initiative Special Populations
The FRAILOMIC Initiative will try to assess if there are some population groups that are at high risk for developing frailty and disability. These are mainly those populations with a high cardiovascular risk profile, which exhibit some differential characteristics regarding the general population of older adults.
Conclusions
The EU places a high priority on healthy ageing. In 2011, with the EU's agreement to launch the Joint Programming Initiative 'More Years, Better Lives', the European Commissioner for Research and Innovation Máire Geoghegan-Quinn stated that 'Europe must work together to tackle challenges such as its ageing population'. The EU went on to make 2012 the 'European Year of Active Ageing and Solidarity between Generations' [46] . The challenges related to an ageing European population have changed over the years. Although there is clear evidence that people are living longer, future forecasts suggest that life expectancy will not be increased substantially, whereas the old age dependency ratio is set to show enormous growth. Hence, the achievement of protracted life expectancy seems less important for the future than reaching an old age that is healthy and potentially free from major disease and disability.
The above-mentioned aims of the FRAILOMIC Initiative will refine the epidemiological concept of frailty using 'omics'-based research methods. Thus, the discovery of biomarkers associated with this condition may provide new biological insights into its aetiology. Furthermore, it will allow us to develop clinical instruments that could be used in the clinic to predict the risk and improve the diagnostic accuracy of frailty as well as assess its prognosis. In this respect, the early detection of subclinical changes afforded by these potential biomarkers could be crucial in allowing for early interventions to prevent/delay frailty and consequently the future onset of disability [9] . The practical outcomes of the FRAILOMIC Initiative promise to build a solid bridge between standard 'care of elderly people' as provided by today's healthcare workers and a more personalised approach to healthcare of older people that would allow us to target limited medical and nursing resources to the individual needs of the patient. The FRAILOMIC Initiative is an ongoing, international, large-scale, multi-endpoint, community-and clinicbased research programme and aims to issue a series of interim scientific reports as key results emerge over the next few years.
